Pre-emptive TAVR in Moderate AS “At-Risk” Patients

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Consultant Fee/Honoraria/Speaker's Bureau - Edwards Lifesciences; Medtronic; Boston Scientific Corporation; Abbott
• Equity/Stock(s)/Options - Excision Medical